Billson J, Clark J, Conway S P, Hart T, Johnson T, Langston S P, Ramjee M, Quibell M, Scott R K
Peptide Therapeutics Group plc, Cambridge, UK.
Bioorg Med Chem Lett. 1998 May 5;8(9):993-8. doi: 10.1016/s0960-894x(98)00151-6.
Prototype irreversible inhibitors of the cysteinyl protease Der p I were designed, synthesised and evaluated in vitro. Candidates were designed using a modular approach, whereby a peptide sequence was appended with known thiophilic moieties. This hinged on utilizing peptide sequences from substrate specificity data compiled using proprietary RAPiD technology.
设计、合成并在体外评估了半胱氨酸蛋白酶Der p I的原型不可逆抑制剂。候选物采用模块化方法设计,即在肽序列上附加已知的亲硫基团。这依赖于利用通过专有RAPiD技术汇编的底物特异性数据中的肽序列。